See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Natural Disasters
Holi
Social Media
Vladimir Putin
Artificial Intelligence
European Union
Android
Education
Coronavirus
Formula 1
Donald Trump
Stock Markets
Published • loading... • Updated

Voyager Reports Positive Topline Data for Single Ascending Dose (SAD) Trial of Anti-Tau Antibody VY7523 and Initiates Multiple Ascending Dose (MAD) Trial in Alzheimer’s Disease - Pipelinereview

Summary by Pipelinereview
– Topline SAD data from healthy volunteers demonstrate safety, tolerability, and dose-proportional pharmacokinetics, supporting potentially best-in-class profile – – MAD study initiated in patients with early Alzheimer’s disease; initial tau PET imaging data expected in H2 2026 – LEXINGTON, MA, USA I March 03, 2025 I Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced …
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All
Left
Center
Right
pipelinereviewpipelinereview

Voyager Reports Positive Topline Data for Single Ascending Dose (SAD) Trial of Anti-Tau Antibody VY7523 and Initiates Multiple Ascending Dose (MAD) Trial in Alzheimer’s Disease - Pipelinereview

– Topline SAD data from healthy volunteers demonstrate safety, tolerability, and dose-proportional pharmacokinetics, supporting potentially best-in-class profile – – MAD study initiated in patients with early Alzheimer’s disease; initial tau PET imaging data expected in H2 2026 – LEXINGTON, MA, USA I March 03, 2025 I Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced …

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

pipelinereview broke the news in on Monday, March 3, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Alzheimer's Disease

Alzheimer's Disease

Lexington, Massachusetts

Lexington, Massachusetts

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
Search
BlindspotLocal